FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a novel derivative of N-acylanthranilic acid, represented by the following general formula 1, or to its pharmaceutically acceptable salt, in which R1, R2, R3, X1, X2, X3, X4 and A are determined in the invention formula.
EFFECT: invention relates to an inhibitor of collagen production, a medication for treating diseases, associated with the excessive production of collagen, containing N-acylanthranilic acid derivative Formula 1.
Title | Year | Author | Number |
---|---|---|---|
NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | 2005 |
|
RU2394021C2 |
CONDENSED AMINOHYDROTHIAZINE DERIVATIVE | 2009 |
|
RU2476431C2 |
SYNTHETIC INTERMEDIATE COMPOUND 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE THIONUCLEOSIDES COMPOUND AND METHOD FOR THEIR PRODUCTION | 2013 |
|
RU2633355C2 |
ARYL-SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | 2010 |
|
RU2575168C2 |
MONOCYCLIC PYRIDINE DERIVATIVE | 2014 |
|
RU2645352C2 |
4-AMINOMETHYLBENZOIC ACID DERIVATIVES | 2014 |
|
RU2673245C2 |
ACYLBENZENE DERIVATIVES | 2011 |
|
RU2585765C2 |
AMINE COMPOUND AND ITS APPLICATION IN MEDICINAL PURPOSES | 2006 |
|
RU2433117C2 |
C-PHENYL GLYCITOL COMPOUND FOR TREATING DIABETES | 2007 |
|
RU2437876C2 |
PYRAZOLE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2016 |
|
RU2687245C1 |
Authors
Dates
2014-10-10—Published
2010-01-29—Filed